Eligibilty

Gender



Age Group



More options for age range

Dates

Names

Showing 1 - 5 of 8 results
Page 1 of 2   

Aspire

Principal Investigator: Sif Hansdottir, MD

Department:Department or Field of Study

Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution 

Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.

Please refer to www.clinicaltrials.gov for more information identifier NCT01266265

age group:1 to 99 years trial start date:April 11, 2011
Gender Preference:none Trial End Date: January 21, 2015
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew RN 319-356-1028  pager # 2123

cynthia-larew@uiowa.edu

Keywords: Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso

Ikaria

Principal Investigator:Sif Hansdottir, MD

Department:Department or Field of Study

This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).

 

Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information. 

age group:18 to 80 years trial start date:April 20, 2012
Gender Preference:none Trial End Date: September 24, 2014
Contact Info:

Pulmonary Hypertension Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

ABS-LT

Principal Investigator: Sif Hansdottir, MD

Department:Department or Field of Study

ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension

This Phase 3, international, multicenter, open-label study will monitor the long-term safety of ambrisentan in subjects with PH. The available ambrisentan doses for this study are 2.5, 5, or 10 mg once daily (qd); the approved doses in the United States, Canada, and the European Union are 5 and 10 mg ambrisentan qd. Investigators will be able to adjust ambrisentan dose as clinically indicated. Ambrisentan can be increased or decreased in one-step intervals, with a minimum of 4 weeks between dose adjustments. Subjects receiving other therapies for PH that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in this study and continue to receive such therapies.

 

This study is closed to enrollment and in the follow-up phase.

 

Please refer to www.clinicaltrials.gov identifier: NCT00777920 for more information.

age group:18 to 99 years trial start date:June 1, 2008
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Pulmonary Hypertension Program

Page Scovel, RN

Phone:  319-356-1028

Fax;  319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Heart ; High blood pressure in lungs ; PAH ; PH ; pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

AMBITION

Principal Investigator:Sif Hansdottir, MD

Department:Department or Field of Study

AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) 

The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.

 

This trial is closed to enrollment,

Please refer to www.clinicaltrials.gov identifier NCT01178073 for more information.

age group:18 to 75 years trial start date:August 10, 2007
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Pulmonary Hypertension Program

Page Scovel, RN

Phone:  319-385-8005

Fax:  319-356-7087

page-scovel@uiowa.edu

Keywords: Heart ; high blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

LEPHT

Principal Investigator: KellyAnn Light-McGroary, MD

Department:Department or Field of Study

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

This study is closed to enrollment and is in follow-up phase.

Please refer to www.clinicaltrials.gov identifier NCT01065454 for more information. 

age group:18 to 80 years trial start date:April 1, 2010
Gender Preference:none Trial End Date: May 31, 2017
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu

Keywords: cardiac disease ; Cardiomyopathy ; Congestive heart failure ; Heart ; Heart failure ; Left ventricular systolic dysfunction ; Pulmonary hypertension ; Pulmonary hypertension associated with left heart
Page 1 of 2
« 1 2 » 
Results per page
5 | 15 | 25

Clinical Research Studies

Filter By Started within
Show trials started in last 1 month
Your Selections

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x